Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the impact of post-transplant cyclophosphamide prophylaxis on graft-versus-host disease (GvHD) in haploidentical transplantation. Prof. Nagler first highlights the importance of post-transplant cyclophosphamide, and then explains how the safety and efficacy of transplant have improved with the use of this agent. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.